Search

Your search keyword '"Hermans, Lucas e."' showing total 33 results

Search Constraints

Start Over You searched for: Author "Hermans, Lucas e." Remove constraint Author: "Hermans, Lucas e."
33 results on '"Hermans, Lucas e."'

Search Results

2. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

3. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.

4. Defective proviruses significantly impact viral transcription and immune activation in men and women with HIV-1 subtype C in rural South Africa.

5. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study

7. Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART

8. Immune activation correlates with and predicts CXCR4 co-receptor tropism switch in HIV-1 infection

10. Predictors of Treatment Adherence and Virological Failure Among People Living with HIV Receiving Antiretroviral Therapy in a South African Rural Community: A Sub-study of the ITREMA Randomised Clinical Trial

11. Predictors of Treatment Adherence and Virological Failure Among People Living with HIV Receiving Antiretroviral Therapy in a South African Rural Community: A Sub-study of the ITREMA Randomised Clinical Trial

12. Prevalence, incidence and recurrence of sexually transmitted infections in HIV-negative adult women in a rural South African setting

13. Unmasking a silent killer: Prevalence of diagnosed and undiagnosed Diabetes Mellitus among people living with HIV in rural South Africa

14. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

15. Unmasking a silent killer: Prevalence of diagnosed and undiagnosed diabetes mellitus among people living with HIV in rural South Africa

17. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

18. A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch

20. HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment

21. A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch: week 96 results of the ITREMA trial

22. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.

23. Changing character and waning impact of COVID-19 at a tertiary centre in Cape Town, South Africa.

24. Differentiated service delivery for people using second‐line antiretroviral therapy: clinical outcomes from a retrospective cohort study in KwaZulu‐Natal, South Africa

25. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study

26. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study

27. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study

28. Immune activation correlates with and predicts CXCR4 co-receptor tropism switch in HIV-1 infection

29. Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART

30. Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries

31. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes : A multicentre cohort study

32. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: A multicentre cohort study

33. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.

Catalog

Books, media, physical & digital resources